BDI Pharma Q2 Revenues Rise; Sales and Distribution for 2011 Maintain Momentum

Share Article

Specialty biotech distributor BDI Pharma announced that Sales Revenues for the second fiscal quarter of 2011 represented an increase of more than twenty-three percent (23%) compared with the same time period in 2010, with the Oncology and Animal Health division continuing to track ahead of 2010 in both revenue and distribution for the quarter and the year, as well.

News Image
Our continued success in this environment provides further validation to the capability of BDI to effectively assist our trade partners in the commercialization process, sales promotion and distribution of these drugs in both measure and methodology.

BDI Pharma, Inc. (BDI), the nation's fastest growing national distributor of specialty biotherapeutics, announced that Sales Revenues for the second fiscal quarter of 2011 represented an increase of more than twenty-three percent (23%) compared with the same time period in 2010. The company's Hemophilia portfolio, an integral component of BDI's Protein Biotherapeutics product line division, provided significant impetus for this growth, as unit distribution for this unique category of drug recorded growth in excess of forty percent (40%) over that of Q2 2010. Other key lines from that same division, Intravenous Immune Globulin (IVIG) and Albumin(Human), also reflected strong increases over the same period in comparison. The Oncology and Animal Health division continue to track ahead of 2010 in both revenue and distribution for the quarter and the year, as well.

"The distribution of specialty pharmaceuticals is not a simple process. The biopharmaceuticals that comprise this ever-growing segment of the broader pharmaceutical marketplace have as many unique requirements, restrictions and points of oversight as do each of the varied medical conditions they treat," said William A. Shirey, III, Executive Vice President of BDI Pharma. "Our continued success in this type of environment provides further validation to the capability of BDI to effectively assist our trade partners in the commercialization process, sales promotion and distribution of these drugs in both measure and methodology consistent with the highest of industry standards."

About BDI Pharma, Inc.

Since 1995, BDI Pharma has defined its customer-centric approach to serving the nation's healthcare community through innovative supply solutions, unparalleled customer service, extensive product knowledge, 24/7 emergency availability and urgent-need delivery. An open-access resource for reference material, educational literature, market data and online ordering, bdipharma.com (ivig.com) has become an industry-renowned point of reference. Proprietary programs for specialty veterinarians -- 4legpharma.com; product consignment -- consignadvantage.com; flu vaccine pre-booking and general vaccine ordering -- securivax.com; and purchasing/reward programs -- qoreprogram.com and securigam.com round out a family of solutions tailored to the needs of the healthcare community at large.

BDI Pharma’s portfolio includes branded and generic specialty pharmaceuticals, chemotherapy products, vaccines, albumin, IVIG, coagulation factors, high-titer or “hyper” immune globulins, and other specialty injectables. BDI Pharma is recognized as an “ADR,” or Authorized Distributor of Record, for all of the manufacturers it represents.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Brad Davis
Visit website